Exelixis Inc. Stock
Price
Target price
€45.08
€45.08
1.310%
0.585
1.310%
€43.76
20:47 / Tradegate
WKN: 936718 / Symbol: EXEL / Name: Exelixis / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Exelixis Inc. Stock
Exelixis Inc. gained 1.310% today.
The stock is one of the favorites of our community with 28 Buy predictions and 1 Sell predictions.
However, we have a potential of -4.61% for Exelixis Inc. as the target price of 43 € is below the current price of 45.08 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Exelixis Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | 1.310% | 3.453% | 17.448% | 18.558% | 15.511% | 148.367% | 143.275% |
| Ligand Pharmaceuticals | 2.970% | -0.990% | 2.041% | 124.719% | 20.482% | 187.770% | 115.796% |
| United Therapeutics | -0.820% | -6.695% | -4.702% | 63.186% | 8.612% | 128.846% | 229.149% |
| Ionis Pharmaceuticals Inc. | 0.880% | -4.097% | -1.569% | 110.608% | -7.681% | 60.872% | 114.642% |
Comments
Exelixis (EXEL) had its price target raised by HC Wainwright from $54.00 to $56.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (EXEL) had its "buy" rating reaffirmed by TD Cowen.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EXEL provided by MarketBeat
News
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near
Key Points
- Interested in Exelixis, Inc.? Here are five stocks we like better.
- Exelixis is leaning on CABO growth in renal cell carcinoma and neuroendocrine tumors, with management emphasizing
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
A few healthcare companies garner much of the attention in the sector. The list includes Eli Lilly, Johnson & Johnson, UnitedHealth Group, and several others. However, beyond those giants, there are
Exelixis: A Strong Contender in the Cancer Drug Market
Explore the exciting world of Exelixis (NASDAQ: EXEL) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market